Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (21-30 of 161) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|April 20, 2004
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trialFranco Maggiolo, Diego Ripamonti, Gianpietro Gregis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2016
NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe)Franco Maggiolo, Elisa Di Filippo, Daniela Valenti, et al.
Journal of the International Association of Providers of AIDS Care|June 13, 2022
Adherence to and Forgiveness of 3TC/DTG in a Real-World CohortFranco Maggiolo, Daniela Valenti, Rodolfo Teocchi, et al.
Journal of the International Association of Providers of AIDS Care|November 24, 2022
Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir AlafenamideFranco Maggiolo, Daniela Valenti, Rodolfo Teocchi, et al.
Infectious Agents and Cancer|October 7, 2015
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort studyElena Raffetti, Francesco Donato, Francesco Castelli, et al.
The New Microbiologica|February 28, 2023
SARS-CoV-2 infection clinical picture and outcomes in adults living with HIV: a cohort analysisFranco Maggiolo, Laura Comi, Marco Arosio, et al.
The Patient|June 30, 2018
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and LamivudineDavid Wohl, Amanda Clarke, Franco Maggiolo, et al.
Journal of Medical Virology|March 31, 2021
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infectionAnnapaola Callegaro, Daniela Borleri, Claudio Farina, et al.
HIV Clinical Trials|January 31, 2002
Factors associated with the failure of HIV-positive persons to return for scheduled medical visitsClaudio Arici, Diego Ripamonti, Franco Maggiolo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2025
Adherence and Forgiveness of Two Modern ART Regimens: Lamivudine/Dolutegravir and Emtricitabine/Tenofovir Alafenamide/RilpivirineLucia Taramasso, Franco Maggiolo, Daniela Valenti, et al.
Pageof 17

Showing results (21-30 of 161) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|April 20, 2004
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trialFranco Maggiolo, Diego Ripamonti, Gianpietro Gregis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2016
NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe)Franco Maggiolo, Elisa Di Filippo, Daniela Valenti, et al.
Journal of the International Association of Providers of AIDS Care|June 13, 2022
Adherence to and Forgiveness of 3TC/DTG in a Real-World CohortFranco Maggiolo, Daniela Valenti, Rodolfo Teocchi, et al.
Journal of the International Association of Providers of AIDS Care|November 24, 2022
Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir AlafenamideFranco Maggiolo, Daniela Valenti, Rodolfo Teocchi, et al.
Infectious Agents and Cancer|October 7, 2015
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort studyElena Raffetti, Francesco Donato, Francesco Castelli, et al.
The New Microbiologica|February 28, 2023
SARS-CoV-2 infection clinical picture and outcomes in adults living with HIV: a cohort analysisFranco Maggiolo, Laura Comi, Marco Arosio, et al.
The Patient|June 30, 2018
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and LamivudineDavid Wohl, Amanda Clarke, Franco Maggiolo, et al.
Journal of Medical Virology|March 31, 2021
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infectionAnnapaola Callegaro, Daniela Borleri, Claudio Farina, et al.
HIV Clinical Trials|January 31, 2002
Factors associated with the failure of HIV-positive persons to return for scheduled medical visitsClaudio Arici, Diego Ripamonti, Franco Maggiolo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2025
Adherence and Forgiveness of Two Modern ART Regimens: Lamivudine/Dolutegravir and Emtricitabine/Tenofovir Alafenamide/RilpivirineLucia Taramasso, Franco Maggiolo, Daniela Valenti, et al.
Pageof 17